ClinConnect ClinConnect Logo
Search / Trial NCT05502484

Development of Self-regulation by Dialectial Behavioural Therapy in Adults With Autism

Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Aug 15, 2022

Trial Information

Current as of July 01, 2025

Enrolling by invitation

Keywords

Autism Spectrum Disorder (Asd) Dialectical Behavioural Therapy (Dbt) Self Regulation Emotion Dysregulation Body Awareness Interoception Sensory Hypersensitivity Sensory Hyposensitivity Non Suicidal Self Injury (Nssi) Suicidal Ideation Suicidal Behaviour Coping Skills

ClinConnect Summary

Individuals with autism spectrum disorder (ASD) are at risk to develop more pervasive emotion-dysregulation and in conjunction with that they also show more maladaptive coping compared to non-autistic people. Sensory differences and impaired interoceptive body-awareness may influence emotion-dysregulation. Maladaptive coping is reflected by a variety of harmful behaviours, particularly strong social avoidance, rumination, obsessive-compulsive symptoms, disordered eating, substance abuse, agitation, non-suicidal-self-injury (NSSI), and suicidal ideation and behaviour. For a part of these ind...

Gender

ALL

Eligibility criteria

  • The inclusion criteria to enroll in the study are the same as the inclusion criteria for integrative DBT. Inclusion Criteria:
  • Age ≥ 18 years old.
  • A clinical diagnosis of ASD as diagnosed by a qualified health care professional (in Dutch: BIG registration).
  • Non-responding to TAU (treatment as usual) for at least a year.
  • IQ ≥ 85, based upon previous levels of education or previous IQ test, when available.
  • Consent from the participant to record the DBT sessions on video or audio for supervision and assessing therapy integrity.
  • Proficient in the Dutch language.
  • Motivation to address problems through integrative DBT.
  • Ability to work on treatment goals in collaboration with multiple therapists and counselors and to function in a group of maximal 8 adults with ASD.
  • Exclusion Criteria:
  • - Severe, current psychotic and manic symptoms, severe substance abuse disorder and eating disorder, requiring other specialized treatment first.

About Radboud University Medical Center

Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.

Locations

Deventer, Gelderland, Netherlands

Patients applied

0 patients applied

Trial Officials

Ella Lobregt-van Buuren, MSc

Principal Investigator

Dimence mental health institute

Nanda Lambregts-Rommelse, PhD

Study Chair

Radboud University Medical Center

Wouter Staal, PhD

Study Chair

Radboud University Medical Center

Lisette Verhoeven, PhD

Study Chair

Dr. Leo Kannerhuis

Peter Goossens, PhD

Study Chair

Dimence mental health institute

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials